Optiver Holding’s Syndax Pharmaceuticals SNDX Stock Holding History

Optiver Holding’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.03K	Sell	230 -113	-33%	-$2.35K	﹤0.01%	1980
2026 Q1	$8.01K	Buy	343 +175	+104%	+$3.8K	﹤0.01%	1273
2025 Q4	$3.53K	Sell	168 -551	-77%	-$9.61K	﹤0.01%	1633
2025 Q3	$11.1K	Buy	719 +208	+41%	+$2.72K	﹤0.01%	1232
2025 Q2	$4.79K	Buy	511 +240	+89%	+$2.64K	﹤0.01%	1207
2025 Q1	$3.33K	Buy	+271	New	+$3.82K	﹤0.01%	1174
2022 Q1	–	Sell	-5,147	Closed	-$98K	–	830
2021 Q4	$98K	Hold	5,147	–	–	﹤0.01%	311
2021 Q3	$98K	Sell	5,147 -3,993	-44%	-$66.5K	﹤0.01%	261
2021 Q2	$157K	Buy	+9,140	New	+$167K	﹤0.01%	222

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Optiver Holding's SNDX Position: Q2 2026 in Review

Optiver Holding reduced its Syndax Pharmaceuticals (SNDX) stake by 33% in Q2 2026, selling an estimated $2.35K and leaving 230 shares worth $5.03K. The position accounts for ﹤0.01% of the portfolio, ranked #1980.

Optiver Holding first reported a position in SNDX in Q2 2021 and has held it in 9 quarters since. The position peaked at $157K in Q2 2021. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Optiver Holding held 230 shares of Syndax Pharmaceuticals worth $5.03K as of Q2 2026.
Optiver Holding sold 113 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.35K.
Syndax Pharmaceuticals made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1980 holding.
Optiver Holding first reported a position in Syndax Pharmaceuticals in Q2 2021 and has held it in 9 quarters since.
Optiver Holding's Syndax Pharmaceuticals position peaked at $157K in Q2 2021.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.